AtriCure Inc

Dilution score: 19/100 (LOW), 24.0 months cash

Short interest: 9.12% of float, squeeze risk: MODERATE

164 PubMed publications found for AtriCure

Performance of Local Large Language Models for Adjudicating Heart Failure Hospitalizations.

Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized Trials.

Edoxaban for atrial fibrillation in patients with atherosclerotic disease in daily clinical practice.

Effectiveness and Safety of Early Rhythm Control in Patients With Atrial Fibrillation and Chronic Kidney Disease.

Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial.

Dilution score: 11/100 (LOW), 999.0 months cash

163 PubMed publications found for AtriCure

Local amiodarone delivery via an extracellular collagen matrix patch to reduce new-onset postoperative atrial fibrillation.

Short interest: 7.95% of float, squeeze risk: MODERATE

162 PubMed publications found for AtriCure

Safety and Efficacy of Stand-Alone and Hybrid Thoracoscopic Atrial Fibrillation Ablation.

Short interest: 7.94% of float, squeeze risk: MODERATE

Congress: 0 buys, 0 sells (1 total trades)

SW convergence: 45/100 (Neutral), 1 bullish / 1 bearish signals

160 PubMed publications found for AtriCure

Tricuspid Valve Academic Research Consortium-2 (TVARC-2): Trial Design and Endpoints.

A randomized controlled trial of pulsed field ablation vs antiarrhythmic therapy as a first-line treatment for persistent atrial fibrillation: The AVANT GUARD trial rationale and design.

Short interest: 7.44% of float, squeeze risk: MODERATE

159 PubMed publications found for AtriCure

Bridging the Digital Divide with Digital Navigation in the California Safety Net: A Mixed-Methods Study.

SW convergence: 45/100 (Neutral), 2 bullish / 2 bearish signals

158 PubMed publications found for AtriCure

Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions.

Short interest: 7.79% of float, squeeze risk: MODERATE

Dilution score: 14/100 (LOW), 24.0 months cash

Short interest: 7.56% of float, squeeze risk: MODERATE

157 PubMed publications found for AtriCure

Tricuspid Valve Academic Research Consortium-2 (TVARC-2) Tricuspid Valve: Trial Design and Endpoints.

Discontinuation of statins by patient and physician sex: An observational study.

<article class="bts-verified-summary" data-ticker="ATRC">
<p>AtriCure Inc (ATRC) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AtriCure+Inc%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

AtriCure Inc (ATRC) — BioTechSigns Verified Summary

AtriCure Inc (ATRC) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov[1].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AtriCure+Inc%22&aggFilters=status%3Arec%2Cact

The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

The primary objective of this registry is to capture real-world safety and performance data on AtriCure devices used to ablate cardiac tissue when treating Inappropriate Sinus Tachycardia (IST) or Postural Tachycardia Syndrome (POTS). This is a retrospective and prospective, multicenter, US/OUS, observational data registry.

Inappropriate Sinus Tachycardia Registry

This is a retrospective and prospective, multicenter, observational patient registry to record outcomes from patients undergoing cryoablation of the intercostal nerves (cryoanalgesia) for post-operative pain management.

A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves

The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

Tracking Results of Ablations to Combat AF Registry Generation 2

Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.

HEAL-IST IDE Trial

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

CONVERGE Post-Approval Study (PAS)

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

The goal of this Registry is to see how the device is used when freezing nerves during an amputation procedure.

Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain

Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial to evaluate if prophylactic ablation and exclusion of the Left Atrial Appendage at the time of other routine cardiac surgery can reduce the incidence of post operative AF and clinical AF during long term follow up in patients who have not yet developed AF but are at risk.